D.E. Shaw & Co
TCRT icon

D.E. Shaw & Co’s Alaunos Therapeutics TCRT Stock Holding History

D.E. Shaw & Co’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,244
Closed -$231K – 5514
2022
Q2 		$231K Sell
1,244
-6,134
-83% -$586K ﹤0.01% 4487
2022
Q1 		$722K Buy
7,378
+975
+15% +$125K ﹤0.01% 4146
2021
Q4 		$1.05M Buy
6,403
+1,268
+25% +$279K ﹤0.01% 3898
2021
Q3 		$1.4M Buy
5,135
+538
+12% +$165K ﹤0.01% 3333
2021
Q2 		$1.82M Sell
4,597
-1,951
-30% -$911K ﹤0.01% 3033
2021
Q1 		$3.54M Buy
6,548
+3,600
+122% +$2.24M ﹤0.01% 2117
2020
Q4 		$1.11M Buy
2,948
+1,205
+69% +$479K ﹤0.01% 2951
2020
Q3 		$659K Sell
1,743
-1,048
-38% -$463K ﹤0.01% 3087
2020
Q2 		$1.37M Buy
+2,791
New +$1.24M ﹤0.01% 2702
2020
Q1 		– Sell
-902
Closed -$639K – 4249
2019
Q4 		$639K Buy
902
+551
+157% +$379K ﹤0.01% 3264
2019
Q3 		$225K Sell
351
-1,622
-82% -$1.29M ﹤0.01% 3587
2019
Q2 		$1.73M Buy
+1,973
New +$1.36M ﹤0.01% 2336
2019
Q1 		– Sell
-3,534
Closed -$991K – 3917
2018
Q4 		$991K Buy
3,534
+1,005
+40% +$397K ﹤0.01% 2667
2018
Q3 		$1.21M Buy
2,529
+1,744
+222% +$748K ﹤0.01% 2561
2018
Q2 		$356K Buy
785
+217
+38% +$138K ﹤0.01% 3293
2018
Q1 		$334K Buy
568
+143
+34% +$89.1K ﹤0.01% 3099
2017
Q4 		$264K Sell
425
-531
-56% -$382K ﹤0.01% 3294
2017
Q3 		$880K Buy
956
+830
+659% +$737K ﹤0.01% 2564
2017
Q2 		$117K Buy
+126
New +$124K ﹤0.01% 3252
2017
Q1 		– Sell
-103
Closed -$82K – 3594
2016
Q4 		$82K Sell
103
-54
-34% -$48.7K ﹤0.01% 3359
2016
Q3 		$133K Buy
+157
New +$126K ﹤0.01% 3260
2016
Q1 		– Sell
-450
Closed -$560K – 3759
2015
Q4 		$560K Buy
450
+357
+384% +$590K ﹤0.01% 3019
2015
Q3 		$126K Sell
93
-197
-68% -$325K ﹤0.01% 3586
2015
Q2 		$522K Sell
290
-2,182
-88% -$3.39M ﹤0.01% 3141
2015
Q1 		$3.99M Buy
2,472
+699
+39% +$1.04M 0.01% 1528
2014
Q4 		$1.35M Buy
1,773
+1,469
+483% +$780K ﹤0.01% 2597
2014
Q3 		$120K Sell
304
-244
-45% -$118K ﹤0.01% 3966
2014
Q2 		$331K Buy
548
+254
+86% +$141K ﹤0.01% 3784
2014
Q1 		$202K Sell
294
-362
-55% -$242K ﹤0.01% 4081
2013
Q4 		$428K Buy
656
+570
+663% +$339K ﹤0.01% 3817
2013
Q3 		$51K Buy
+86
New +$38.8K ﹤0.01% 4233

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

D.E. Shaw & Co's TCRT Position: Q3 2022 in Review

D.E. Shaw & Co sold out of Alaunos Therapeutics (TCRT) in Q3 2022, closing a stake of 1,244 shares — an estimated $231K sold.

D.E. Shaw & Co first reported a position in TCRT in Q3 2013 and held it in 31 quarters. The position peaked at $3.99M in Q1 2015. 125 funds tracked by Wall St. Rank hold TCRT as of Q3 2022.

  • D.E. Shaw & Co reported no remaining Alaunos Therapeutics position as of Q3 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 1,244 Alaunos Therapeutics shares in Q3 2022, an estimated $231K.
  • D.E. Shaw & Co first reported a position in Alaunos Therapeutics in Q3 2013 and held it in 31 quarters.
  • D.E. Shaw & Co's Alaunos Therapeutics position peaked at $3.99M in Q1 2015.
  • 125 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.